74 F. Supp. 3d 1052
N.D. Cal.2014Background
- Endo (marketer) and Teikoku (manufacturer/patent owner) settled patent litigation with Watson (ANDA filer) after trial but before judgment, agreeing Watson would delay launching its generic Lidoderm until Sept. 15, 2013.
- Settlement terms: $96 million in branded product to Watson (eight monthly transfers), a prohibition on Endo releasing an authorized generic for 7.5 months after Watson’s launch, dismissal of suits and cessation of a Citizen Petition, and a 25% royalty on Watson’s gross profit during exclusivity (plaintiffs estimate total value ≈ $266M).
- Plaintiffs (direct purchasers, end-payors, and GEHA) allege the settlement constituted large, unjustified reverse payments that violated Section 1 (Sherman Act) under the rule-of-reason framework from F.T.C. v. Actavis and caused antitrust injury by delaying lower-priced generics.
- Defendants moved to dismiss, arguing (inter alia) that the challenged terms were not payments (non-monetary/early-entry), the payments were justified by litigation costs and procompetitive effects, Section 2 claims required pleading single-entity monopoly power, and many state-law claims lacked standing or were barred by Illinois Brick.
- The court denied dismissal of DPPs’ Sherman Act §1 rule-of-reason claim (reverse payments plausible and valuated), granted dismissal of the §1 per se theory as to the no-authorized-generic term, granted leave to amend Section 2 monopolization-related claims, and resolved multiple state-law standing and Illinois Brick issues (some dismissals with prejudice, others with leave to amend).
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether settlement included a reverse payment | The branded transfers of $96M in product plus no-authorized-generic constituted reverse payments inducing delay | These terms merely allowed early entry and aren’t "payments" under Actavis (cash-only) | Court: plausible reverse payments; non-cash transfers (brand product, no-AG) can be "payments" and survive dismissal |
| Valuation and whether payments were "large and unjustified" | Payments (~$266M) far exceed litigation costs and lack traditional settlement justification | Plaintiffs failed to plead avoided litigation costs to negate traditional settlement justification | Court: plaintiffs plausibly alleged size/unexplained nature; defendants bear burden to justify—dismissal denied |
| Rule of reason causation/antitrust injury (at-risk entry) | Watson was prepared and willing to launch at-risk upon FDA approval; payments caused delayed entry and harm to consumers | Settlement only allowed early entry and regulatory/patent hurdles made earlier launch speculative | Court: allegations of at-risk readiness (earnings calls, production, FDA approval date) plausible; injury adequately alleged |
| No-authorized-generic term: per se or rule-of-reason | Plaintiffs: no-AG is naked restraint and independently per se illegal | Defendants: no-AG is part of settlement/licensing and not per se naked restraint | Court: no-authorized-generic evaluated under rule of reason per Actavis; per se claim dismissed |
| Section 2 monopolization/attempt/conspiracy claims | Plaintiffs: defendants conspired/monopolized market via settlement | Defendants: Section 2 requires single-firm monopoly power; plaintiffs plead a combined Endo/Teikoku “shared monopoly” | Court: dismissed Section 2 claims (monopoly/attempt/conspiracy) as pleaded against both entities together; granted leave to amend to plead single-entity market power |
| State-law claims, standing, and Illinois Brick/unjust-enrichment end-run | Plaintiffs: EPPs/GEHA can bring indirect purchaser and unjust enrichment claims in many states; GEHA represents nationwide injuries | Defendants: many state claims lack Article III standing (no nexus), some states (IL, MA, PR, RI) bar indirect-purchaser suits or repealer nonretroactive; unjust enrichment cannot circumvent Illinois Brick | Court: resolved state-by-state—multiple state claims dismissed with prejudice (e.g., IL, MA, PR, RI, FL), others dismissed with leave to amend for lack of connection; GEHA limited to Missouri; unjust-enrichment claims barred in jurisdictions that haven’t repealed Illinois Brick; California unjust-enrichment claim dismissed with prejudice |
Key Cases Cited
- F.T.C. v. Actavis, Inc., 133 S. Ct. 2223 (U.S. 2013) (adopts rule-of-reason for reverse-payment settlements; large, unexplained reverse payments can suggest anticompetitive intent)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) (plausibility pleading standard for Rule 12(b)(6))
- Ashcroft v. Iqbal, 556 U.S. 662 (U.S. 2009) (legal conclusions insufficient; factual plausibility required)
- Illinois Brick Co. v. Illinois, 431 U.S. 720 (U.S. 1977) (indirect purchasers barred from federal antitrust damages absent state repealer)
- California Dental Ass’n v. F.T.C., 224 F.3d 942 (9th Cir. 2000) (rule-of-reason framework elements)
- Rebel Oil Co. v. Atl. Richfield Co., 51 F.3d 1421 (9th Cir. 1995) (antitrust standing and antitrust injury require consumer-welfare focus)
- Texaco Inc. v. Dagher, 547 U.S. 1 (U.S. 2006) (joint ventures can be treated as single entity for antitrust analysis)